Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases


UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co., LTD. (Osaka, Japan, 'Ono') has exercised its option under an agreement executed in April 2014 to enter into a new research and license agreement utilizing Merus' proprietary Biclonics® technology platform to generate a bispecific antibody that binds to a combination of targets designed for the treatment of autoimmune diseases.  

"Ono's decision to exercise its option builds on the success to date of the original collaboration we entered into in 2014," said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. "As we continue to advance and expand Merus' proprietary pipeline of innovative therapeutic candidates in oncology, we are very excited to work with a collaborator such as Ono to leverage our Biclonics® technology platform to develop therapeutics for other disease areas with significant unmet medical needs."  

"We highly value Merus' proprietary drug discovery technology which effectively generates full-length human bispecific antibody therapeutics," said Hiromu Habashita, Ph.D., Corporate Officer, and Executive Director of Discovery & Research of Ono. "We are glad to expand our collaboration and look forward to realizing the next generation of high value treatments in autoimmune disease area."

In April 2014, Merus and Ono entered into a research and license agreement to jointly develop bispecific antibody therapies for autoimmune diseases. In 2016, Ono selected a lead bispecific antibody candidate that it intends to advance into clinical testing, which triggered a milestone payment to Merus. By exercising its option under the terms of the first agreement, Ono has agreed to fund research activities at Merus that will generate candidate Biclonics® for the new program. Merus has granted Ono worldwide exclusive rights to develop, manufacture, and commercialize the resulting products developed through the collaboration. 

Consistent with the terms of Merus' 2014 agreement, under the new agreement, Merus will receive an undisclosed upfront payment. Merus is also eligible to receive milestone payments upon achievement of specified research and clinical development milestones. For products commercialized under this agreement, if any, Merus is also eligible to receive a mid-single digit royalty on net sales.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Merus' second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus' website,

About Ono

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas. For more information, please visit the company's website at

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the development and commercialization of a bispecific antibody that binds to a combination of targets designed for the treatment of autoimmune diseases under the new agreement between Merus and Ono, the progress and timing of the clinical activities as part of the collaboration with Ono, the value of the collaboration to Merus and Ono, Merus' receipt of the upfront payment from Ono, the advancement and expansion of Merus' proprietary pipeline of therapeutic candidates in oncology, the ability to leverage Merus' Biclonics® technology platform to develop therapeutic candidates, the design, treatment potential, clinical development and clinical development plans for Merus' bispecific antibody therapeutic candidates.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics® and bispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaboration with Incyte or Incyte may fail to perform adequately under our collaboration; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in existing and potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.

These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 28, 2017, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.


Kimberly Minarovich 
+1 646 368 8014

David Rosen
+1 212-600-1902

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire




Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Auth0 Announces Key Distribution Partnership with AppXite20.3.2018 10:00Pressmeddelande

End-to-end identity management now available to all AppXite resellers LONDON, March 20, 2018 (GLOBE NEWSWIRE) -- Auth0, a global leader in Identity-as-a-Service (IDaaS), has announced a new partnership with AppXite, a global leader in SaaS solutions aggregation and fully owned subsidiary of Atea. Auth0's identity and access management platform will be added to AppXite's SaaS offering, adding even more value to its global reseller offering. Auth0's Universal Identity platform will now be accessible to AppXite's extensive global network of managed service providers (MSPs), value-added resellers (VARs), and systems integrators (SIs) around the world. AppXite's reseller network can integrate Auth0's identity platform into their own offering to increase profitability, expand market share, and help their customers thrive in today's cloud economy. "Over the past few years, we have noticed a marked increase in demand for identity management. Companies are realizing the complexity of trying to

McDonald's Becomes the First Restaurant Company to Set Approved Science Based Target to Reduce Greenhouse Gas Emissions20.3.2018 09:03Pressmeddelande

Company Expected to Prevent 150 Million Metric Tons of Emissions by 2030 OAK BROOK, Ill., March 20, 2018 (GLOBE NEWSWIRE) -- Today, McDonald's announces it will partner with franchisees and suppliers to reduce greenhouse gas emissions related to McDonald's restaurants and offices by 36% by 2030 from a 2015 base year in a new strategy to address global climate change. Additionally, McDonald's commits to a 31% reduction in emissions intensity (per metric ton of food and packaging) across its supply chain by 2030 from 2015 levels. This combined target has been approved by the Science Based Targets initiative(SBTi). Through these actions, McDonald's expects to prevent 150 million metric tons of greenhouse gas emissions from being released into the atmosphere by 2030. This is the equivalent of taking 32 million passenger cars off the road for an entire year or planting 3.8 billion trees and growing them for 10 years. The target will enable McDonald's to grow as a business without growing it

Momentum Group acquires Reklamproffsen in Örebro20.3.2018 08:45Pressmeddelande

Momentum Group AB (publ) has acquired 70 percent of the shares in Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen is a leading reseller of promotional products, including workwear and profile clothing, in Örebro and the surrounding area. Reklamproffsen generates annual revenue of approximately MSEK 35 with favourable profitability and has 12 employees. Reklamproffsen is one of Örebro's largest resellers of workwear and profile clothing, with a high level of expertise in customising company products. Reklamproffsen has a professional store and showroom in Örebro. Its customers mainly comprise industrial and service companies, and a significant portion of its sales are conducted via customised online stores. "Thanks to its strong customer and supplier relationships and highly skilled employees, Reklamproffsen has achieved successful growth since it was formed in 2000. It is now a well-established company in Örebro and the surrounding area. We anticipate good opportuniti

Momentum Group förvärvar Reklamproffsen i Örebro20.3.2018 08:45Pressmeddelande

Momentum Group AB (publ) har förvärvat 70 procent av aktierna i Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen är en ledande återförsäljare av produktmedia innefattande yrkeskläder och profilkläder i Örebro med omnejd. Reklamproffsen omsätter cirka 35 MSEK per år med god lönsamhet och har 12 anställda. Reklamproffsen är en av Örebros största återförsäljare inom yrkeskläder och profilkläder med hög kompetens inom företagsprofilering. Reklamproffsen har en yrkesbutik och utställning i Örebro. Kunderna utgörs främst av industri- och serviceföretag och en betydande andel av försäljningen sker via kundunika webbshoppar. - Reklamproffsen har med sina starka kund- och leverantörsrelationer och medarbetare med hög kompetens utvecklats framgångsrikt ända sedan starten år 2000. Bolaget är idag ett väletablerat företag i Örebro med omnejd. Vi ser mycket goda möjligheter till vidare utveckling och tillväxt för Reklamproffsen som en del av Momentum Group, säger Ulf Lilius, VD & K

Immunicum AB: Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data20.3.2018 08:00Pressmeddelande

Press Release 20 March 2018 Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today that its lead product candidate, ilixadencel, has been granted an Advanced Therapy Medicinal Product (ATMP) certificate following a review of manufacturing quality and non-clinical data by the European Medicines Agency (EMA). "The EMA ATMP certificate is an important development milestone for ilixadencel because it validates our manufacturing quality and preclinical data and gives us a firm foundation for the later stages of clinical development. Cell-based therapies must meet very high requirements and we are pleased to have this recognition from the EMA of our work to date," said Carlos de Sousa, CEO of Immunicum. "Immunicum is one of very few companies that have successfully u

Immunicum AB: Immunicum AB (publ) meddelar att ilixadencel har beviljats ATMP-certifiering från EMA gällande tillverkningskvalitet och prekliniska data20.3.2018 08:00Pressmeddelande

Pressmeddelande 20 mars 2018 Immunicum AB (publ) meddelar att ilixadencel har beviljats ATMP-certifiering från EMA gällande tillverkningskvalitet och prekliniska data Immunicum AB (publ; IMMU.ST) ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelar idag att bolagets ledande produktkandidat, ilixadencel, har erhållit en ATMP-certifiering (Advanced Therapy Medicinal Product) efter granskning av tillverkningskvalitet och prekliniska data av den europeiska läkemedelsmyndigheten EMA (European Medicines Agency). "EMAs ATMP certifikat är en viktig milstolpe i utvecklingen av ilixadencel eftersom det validerar vår tillverkningskvalitet och våra prekliniska data, och ger oss samtidigt en solid bas för de senare faserna i den kliniska utvecklingen. Cell-baserade terapier måste uppfylla mycket höga krav och vi är glada att få detta erkännande av EMA för vårt arbete så här långt," säger Carlos de Sousa, VD för Immunicum. "Immunicum ä

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum